

# CONTENTS

		<b>PAGE</b>
ENGLISH ABSTRACT		ii
THAI ABSTRACT		iv
ACKNOWLEDGEMENTS		vi
CONTENTS		vii
LIST OF TABLES		x
LIST OF FIGURES		xi
<b>CHAPTER</b>		
<b>1</b>	<b>INTRODUCTION</b>	<b>1</b>
1.1	Background	1
1.2	Objective	2
1.3	Scope of work	2
<b>2</b>	<b>THEORIES AND LITERATURE REVIEW</b>	<b>3</b>
2.1	Acute kidney injury	3
2.2	Biomarkers	3
2.2.1	Kidney injury molecule-1 (KIM-1)	3
2.2.2	Interleukin-18 (IL18)	4
2.2.3	N-Acetyl- $\beta$ -D-glucosaminidase (NAG)	4
2.2.4	Cystatin C	4
2.2.5	Neutrophil gelatinase associated lipocalin (NGAL)	5
2.3	Immunoassay	6
2.4	The methods of NGAL detection	8
2.4.1	Enzyme-linked immunosorbent assay (ELISA)	8
2.4.2	Architect	9
2.4.3	Triage	10
2.4.4	Lateral flow immunoassay	10
2.5	Carbon nanoparticles	12
2.6	Dot blot test	13
2.7	Previous works	13
<b>3</b>	<b>METHODOLOGY</b>	<b>14</b>
3.1	Reagents and materials	14
3.2	Equipments	15
3.3	Methods	15
3.3.1	Preparation of carbon nanoparticles	15
3.3.2	Preparation of buffer	16

	<b>PAGE</b>
3.3.3 Preparation of antibody-carbon nanoparticle conjugate	16
3.3.4 Dot blot test	16
3.3.5 Analysis of urine samples using the dot blot method	17
3.4 The results	17
<b>4 RESULTS AND DISCUSSION</b>	<b>18</b>
4.1 The size of antibody-carbon nanoparticles	18
4.2 Preparation of the antibody-carbon nanoparticle conjugate and the results of each preparation	19
4.2.1 Antibody: Monoclonal anti-NGAL antibody (P5E1) from BBI Solution	19
4.2.2 Antibody: Human Lipocalin-2/NGAL Biotinylated (BAF1757) from R&D system	26
<b>5 CONCLUSIONS AND RECOMMENDATIONS</b>	<b>38</b>
5.1 Conclusions	38
5.2 Recommendation	38
<b>REFERENCES</b>	<b>39</b>
<b>APPENDIX</b>	<b>42</b>
A Calculation of percent carbon conjugate	42
B Size of carbon conjugate after sonication	45
C The data of the intensity from an Image J program	47
<b>CURRICULUM VITAE</b>	<b>50</b>

## LIST OF TABLES

<b>TABLE</b>		<b>PAGE</b>
4.1	The percent of carbon conjugate at 350 µg/ml in 0.2% (w/v) carbon suspension of antibody concentration	20
4.2	The percent of carbon conjugate at 350 µg/ml in 1.0% and 2.0% (w/v) carbon suspension of anti-NGAL antibody concentration	25
4.3	The intensities of each spot of CARBON1 and CARBON3	29
4.4	The intensities of each spot of CARBON1, CARBON3 and CARBON4	33
4.5	The intensities of each spot of CARBON3 and CARBON5	35
A.1	Absorbance at 562 nm of BSA standard curve for measuring protein at 350µg/ml of anti-NGAL antibody in 0.2% colloidal carbon suspension	43
A.2	Percent carbon conjugate at 350µg/ml in 0.2% colloidal carbon suspension	43
A.3	Absorbance at 562 nm of BSA standard curve for measuring protein at 350µg/ml of anti-NGAL antibody in 1.0% and 2.0% colloidal carbon suspension	43
A.4	Percent carbon conjugate at 350µg/ml in 1.0% and 2% colloidal carbon suspension	44
B.1	Size of carbon conjugate after sonication	46
C.1	The intensity from an Image J program in section 4.2.2.1.1	48
C.2	The intensity from an Image J program in section 4.2.2.1.2	48
C.3	The intensity from an Image J program in section 4.2.2.1.3	49

## LIST OF FIGURES

FIGURE	PAGE
2.1 Pattern of urinary biomarker expression of KIM-1, NGA and NGAL at different time after cardiac surgeries	5
2.2 The label free assays	6
2.3 The reagent excess assays	7
2.4 The reagent limited assay	7
2.5 The ELISA plates	8
2.6 The formats of ELISA	9
2.7 Direct solid-phase immunoassay	10
2.8 Competitive assay	11
2.9 Typical shape of a lateral flow immunoassay test strip	12
3.1 The results of dot blot method	17
4.1 The trend of size of carbon conjugate after sonication	18
4.2 Varying 0.2% (w/v) carbon suspension in antibody-carbon nanoparticle conjugate	19
4.3 BSA standard curve from Micro BCA™ Reagent Protein Assay (0-20µg/ml)	20
4.4 Flow of 0.2% (w/v) antibody-carbon nanoparticle conjugate with a concentration on the membrane previously spotted with various concentrations of NGAL protein at 2 µL/spot	21
4.5 Flow of 0.2% (w/v) antibody-carbon nanoparticle conjugate with a concentration on the membrane previously spotted with various concentrations of NGAL protein at 1 µL/spot	21
4.6 Dot blot of antibody-carbon nanoparticle conjugate with a concentration 0.2% (w/v) carbon suspension on the membrane with 1 µL/spot of each concentration of protein	22
4.7 The color intensity of the highest concentration of BSA standard curve (40 µg/ml) and sample	23
4.8 Varying 1.0% (right) and 2.0% (left) (w/v) carbon suspension in antibody-carbon nanoparticle conjugate	24
4.9 BSA standard curve from Micro BCA™ Reagent Protein Assay (0-20µg/ml)	24
4.10 Flow of antibody-carbon nanoparticle conjugate with a concentration 1.0 % and 2.0% (w/v) carbon suspension on the membrane with 1 µL/spot of each concentration of protein	25
4.11 Varying the ratio of carbon suspension and antibody at 5000:1 in different speed: 150 rpm (left) and 200 rpm (right)	26
4.12 The first set of the experiment: a) after scanning b) after scanning and inverting.	27
4.13 The second set of the experiment: a) after scanning b) after scanning and inverting	28

<b>FIGURE</b>	<b>PAGE</b>
4.14 The third set of the experiment: a) after scanning b) after scanning and inverting	29
4.15 Varying the ratio of carbon suspension and antibody at 2000:1 (left) and 667: 1 (right)	30
4.16 The first set of the experiment: a) after scanning b) after scanning and inverting	31
4.17 The second set of the experiment: a) after scanning b) after scanning and inverting.	31
4.18 The third set of the experiment: a) after scanning b) after scanning and inverting	32
4.19 The failure of lateral flow on the membrane: 17. CARBON1, 22. CARBON3, 26. and 27. CARBON4	32
4.20 Repeating the ratio of carbon suspension and antibody to 2000:1	34
4.21 The first set of the experiment: a) after scanning b) after scanning and inverting	34
4.22 The second set of the experiment: a) after scanning b) after scanning and inverting	35
4.23 The scanning and inverting photo: membrane (left) and glass slide (right)	36